<?xml version='1.0'?><!DOCTYPE Annotation PUBLIC "//GENIA//DTD GENIA ANNOTATION EVENT 2.0//EN_Modified" "../ModifiedGENIAtypes/Modified_GENIA_event_20.dtd"><Annotation annotates="http://www.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;retmode=xml&amp;rettype=medline&amp;id=9416887" created="29/03/2006" creator="Noriko Katsu"><PubmedArticleSet><PubmedArticle><MedlineCitation>
<PMID>9416887</PMID>
<Article>
<ArticleTitle>
<sentence id="S1"><term id="T1" lex="cyclosporin_A" sem="Organic_compound_other">Cyclosporin A</term> inhibits <term id="T2" lex="monocyte_tissue_factor_activation" sem="Other">monocyte <term id="T3" lex="tissue_factor" sem="Protein_family_or_group">tissue factor</term> activation</term> in <term id="T4" lex="cardiac_transplant_recipient" sem="Multicellular_organism_natural">cardiac transplant recipients</term>.</sentence>
<event KT="Other" id="E1">
<type class="Positive_regulation"/>
<theme idref="T3"/>
<clue>Cyclosporin A inhibits <clueLoc>monocyte</clueLoc> tissue factor <clueType>activation</clueType> in cardiac transplant recipients.</clue>
</event>
<event id="E2">
<type class="Negative_regulation"/>
<theme idref="E1"/>
<cause idref="T1"/>
<clue>Cyclosporin A <clueType>inhibits</clueType> monocyte tissue factor activation <clueLoc>in cardiac transplant recipients</clueLoc>.</clue>
</event>
</ArticleTitle>
<Abstract>
<AbstractText>
<sentence id="S2">BACKGROUND: <term id="T5" lex="fibrin_deposition" sem="Other"><term id="A2" sem="Protein_molecule">Fibrin</term> deposition</term> and <term id="T6" lex="thrombosis" sem="Other">thrombosis</term> have been implicated in both <term id="T7" lex="allograft_rejection" sem="Other"><term id="A3" sem="Body_region">allograft</term> rejection</term> and <term id="T8" lex="vasculopathy" sem="Other">vasculopathy</term> after <term id="T9" lex="cardiac_transplantation" sem="Other">cardiac transplantation</term>.</sentence>
<event KT="Other" id="E3">
<type class="Localization"/>
<theme idref="A2"/>
<clue>BACKGROUND: Fibrin <clueType>deposition</clueType> and thrombosis have been implicated in both allograft rejection and vasculopathy after cardiac transplantation.</clue>
</event>
<event CL="L2" KT="Analysis" Source="Other" id="E4">
<type class="Negative_regulation"/>
<theme idref="A3"/>
<clue>BACKGROUND: Fibrin deposition and thrombosis <clueSource>have been</clueSource> <clueKT><clueCL>implicated</clueCL></clueKT> in both allograft <clueType>rejection</clueType> and vasculopathy after cardiac transplantation.</clue>
</event>
<sentence id="S3">Because <term id="T10" lex="monocyte" sem="Cell_natural">monocytes</term> play a pivotal role in the pathophysiology of <term id="T11" lex="intravascular_coagulation" sem="Other">intravascular coagulation</term> activation through their ability to synthesize <term id="T12" lex="tissue_factor" sem="Protein_family_or_group">tissue factor</term> (<term id="T13" lex="TF" sem="Protein_family_or_group">TF</term>), we asked (1) whether <term id="T14" lex="monocyte_TF_activation" sem="Other">monocyte <term id="T15" lex="TF" sem="Protein_family_or_group">TF</term> activation</term> occurs in <term id="T16" lex="cardiac_transplant_recipient" sem="Multicellular_organism_natural">cardiac transplant recipients</term> and (2) whether <term id="T17" lex="monocyte_TF_expression" sem="Other">monocyte <term id="T18" lex="TF_expression" sem="Other"><term id="T19" lex="TF" sem="Protein_family_or_group">TF</term> expression</term></term> is affected by treatment with <term id="T20" lex="cyclosporin_A" sem="Organic_compound_other">cyclosporin A</term> (<term id="T21" lex="CsA" sem="Organic_compound_other">CsA</term>).</sentence>
<event KT="Other" id="E5">
<type class="Positive_regulation"/>
<theme idref="T11"/>
<cause idref="E6"/>
<clue>Because monocytes play a pivotal role in the pathophysiology of intravascular coagulation <clueType>activation</clueType> <linkCause>through</linkCause> their ability to synthesize tissue factor (TF), we asked (1) whether monocyte TF activation occurs in cardiac transplant recipients and (2) whether monocyte TF expression is affected by treatment with cyclosporin A (CsA).</clue>
</event>
<event CL="L2" KT="Analysis" id="E6">
<type class="Gene_expression"/>
<theme idref="T12"/>
<clue>Because <clueLoc>monocytes</clueLoc> play a pivotal role in the pathophysiology of intravascular coagulation activation through their <clueKT><clueCL>ability</clueCL></clueKT> to <clueType>synthesize</clueType> tissue factor (TF), we asked (1) whether monocyte TF activation occurs in cardiac transplant recipients and (2) whether monocyte TF expression is affected by treatment with cyclosporin A (CsA).</clue>
</event>
<event KT="Fact" id="E7">
<type class="Regulation"/>
<theme idref="E5"/>
<cause idref="T10"/>
<clue>Because monocytes <clueType>play a pivotal role</clueType> <linkTheme>in</linkTheme> the pathophysiology of intravascular coagulation activation through their ability to synthesize tissue factor (TF), we asked (1) whether monocyte TF activation occurs in cardiac transplant recipients and (2) whether monocyte TF expression is affected by treatment with cyclosporin A (CsA).</clue>
</event>
<event KT="Investigation" id="E8" uncertainty="doubtful">
<type class="Positive_regulation"/>
<theme idref="E33"/>
<clue>Because monocytes play a pivotal role in the pathophysiology of intravascular coagulation activation through their ability to synthesize tissue factor (TF), we <clueKT>asked</clueKT> (1) whether monocyte TF activation <clueType>occurs</clueType> <clueLoc>in cardiac transplant recipients</clueLoc> and (2) whether monocyte TF expression is affected by treatment with cyclosporin A (CsA).</clue>
</event>
<event KT="Other" id="E33">
<type class="Positive_regulation"/>
<theme idref="T15"/>
<clue>Because monocytes play a pivotal role in the pathophysiology of intravascular coagulation activation through their ability to synthesize tissue factor (TF), we asked (1) whether <clueLoc>monocyte</clueLoc> TF <clueType>activation</clueType> occurs in cardiac transplant recipients and (2) whether monocyte TF expression is affected by treatment with cyclosporin A (CsA).</clue>
</event>
<event KT="Investigation" id="E9" uncertainty="doubtful">
<type class="Regulation"/>
<theme idref="E10"/>
<cause idref="T21"/>
<clue>Because monocytes play a pivotal role in the pathophysiology of intravascular coagulation activation through their ability to synthesize tissue factor (TF), we <clueKT>asked</clueKT> (1) whether monocyte TF activation occurs in cardiac transplant recipients and (2) whether monocyte TF expression is <clueType>affected</clueType> <linkCause>by</linkCause> treatment with cyclosporin A (CsA).</clue>
</event>
<event KT="Other" id="E10">
<type class="Gene_expression"/>
<theme idref="T19"/>
<clue>Because monocytes play a pivotal role in the pathophysiology of intravascular coagulation activation through their ability to synthesize tissue factor (TF), we asked (1) whether monocyte TF activation occurs in cardiac transplant recipients and (2) whether <clueLoc>monocyte</clueLoc> TF <clueType>expression</clueType> is affected by treatment with cyclosporin A (CsA).</clue>
</event>
<sentence id="S4">METHODS AND RESULTS: We measured levels of <term id="T22" lex="TF_activity" sem="Other"><term id="T23" lex="TF" sem="Protein_family_or_group">TF</term> activity</term> in <term id="T24" lex="peripheral_blood_mononuclear_cell" sem="Cell_natural">peripheral blood mononuclear cells</term> and <term id="T25" lex="highly_purified_monocyte/macrophage" sem="Cell_natural">highly purified <term id="T26" lex="monocyte" sem="Cell_natural">monocytes</term>/macrophages</term> from 10 consecutive <term id="T27" lex="cardiac_transplant_recipient" sem="Multicellular_organism_natural">cardiac transplant recipients</term> and 10 <term id="T28" lex="healthy_control_subject" sem="Multicellular_organism_natural">healthy control subjects</term>.</sentence>
<sentence id="S5"><term id="T29" lex="TF_activity" sem="Other"><term id="T30" lex="TF" sem="Protein_family_or_group">TF</term> activity</term> generated by both <term id="T31" lex="unstimulated_cell" sem="Cell_cultured">unstimulated</term> and <term id="T32" lex="endotoxin-stimulated_cell" sem="Cell_cultured"><term id="A5" sem="Cell_cultured"><term id="A1" sem="Organic_compound_other">endotoxin</term>-stimulated</term> <term id="A6" sem="Cell_cultured">cells</term></term> was significantly higher in <term id="T33" lex="transplant_recipient" sem="Multicellular_organism_natural">transplant recipients</term> than in <term id="T34" lex="control_subject" sem="Multicellular_organism_natural">control subjects</term> (P&lt;.05).</sentence>
<event Manner="High" id="E13">
<type class="Positive_regulation"/>
<theme idref="T30"/>
<cause idref="T31" idref1="A6"/>
<clue>TF activity <clueType>generated</clueType> <clueLoc>by</clueLoc> both <clueLoc>unstimulated</clueLoc> and endotoxin-stimulated <clueLoc>cells</clueLoc> was <clueManner>significantly higher</clueManner> in transplant recipients than in control subjects (P&lt;.05).</clue>
</event>
<event Manner="High" id="E14">
<type class="Positive_regulation"/>
<theme idref="T29"/>
<clue>TF activity <clueType>generated</clueType> <clueLoc>by</clueLoc> both unstimulated and <clueLoc>endotoxin-stimulated cells</clueLoc> was <clueManner>significantly higher</clueManner> in transplant recipients than in control subjects (P&lt;.05).</clue>
</event>
<event id="E40">
<type class="Physiological_process"/>
<theme idref="A6"/>
<cause idref="A1"/>
<clue>TF activity generated by both unstimulated and endotoxin-<clueType>stimulated</clueType> cells was significantly higher in transplant recipients than in control subjects (P&lt;.05).</clue>
</event>
<sentence id="S6">Increased <term id="T35" lex="monocyte_TF_expression" sem="Other">monocyte <term id="T36" lex="TF_expression" sem="Other"><term id="T37" lex="TF" sem="Protein_family_or_group">TF</term> expression</term></term> in <term id="T38" lex="transplant_recipient" sem="Multicellular_organism_natural">transplant recipients</term> was shown to be adversely affected by treatment with <term id="T39" lex="CsA" sem="Organic_compound_other">CsA</term>: <term id="T40" lex="TF_induction" sem="Other"><term id="T41" lex="TF" sem="Protein_family_or_group">TF</term> induction</term> was markedly reduced by <term id="T42" lex="CsA" sem="Organic_compound_other">CsA</term> serum concentrations reaching peak <term id="T43" lex="CsA_drug_level" sem="Other"><term id="T44" lex="CsA" sem="Organic_compound_other">CsA</term> drug levels</term>.</sentence>
<event KT="Other" id="E12">
<type class="Positive_regulation"/>
<theme idref="E15"/>
<clue><clueType>Increased</clueType> monocyte TF expression in transplant recipients was shown to be adversely affected by treatment with CsA: TF induction was markedly reduced by CsA serum concentrations reaching peak CsA drug levels.</clue>
</event>
<event KT="Other" id="E15">
<type class="Gene_expression"/>
<theme idref="T37"/>
<clue>Increased <clueLoc>monocyte</clueLoc> TF <clueType>expression</clueType> <clueLoc>in transplant recipients</clueLoc> was shown to be adversely affected by treatment with CsA: TF induction was markedly reduced by CsA serum concentrations reaching peak CsA drug levels.</clue>
</event>
<event KT="Analysis" id="E16">
<type class="Negative_regulation"/>
<theme idref="E12"/>
<cause idref="T39"/>
<clue>Increased monocyte TF expression in transplant recipients was <clueKT>shown</clueKT> to be <clueType>adversely affected</clueType> by treatment <linkCause>with</linkCause> CsA: TF induction was markedly reduced by CsA serum concentrations reaching peak CsA drug levels.</clue>
</event>
<event Manner="High" id="E17">
<type class="Negative_regulation"/>
<theme idref="E34"/>
<cause idref="T42"/>
<clue>Increased monocyte TF expression in transplant recipients was shown to be adversely affected by treatment with CsA: TF induction was <clueManner>markedly</clueManner> <clueType>reduced</clueType> <linkCause>by</linkCause> CsA serum concentrations <clueManner>reaching peak</clueManner> CsA drug <clueManner>levels</clueManner>.</clue>
</event>
<event id="E34">
<type class="Positive_regulation"/>
<theme idref="T41"/>
<clue>Increased monocyte TF expression in transplant recipients was shown to be adversely affected by treatment with CsA: TF <clueType>induction</clueType> was markedly reduced by CsA serum concentrations reaching peak CsA drug levels.</clue>
</event>
<sentence id="S7">Inhibition of <term id="T45" lex="TF_induction" sem="Other"><term id="T46" lex="TF" sem="Protein_family_or_group">TF</term> induction</term> in the presence of high <term id="T47" lex="CsA" sem="Organic_compound_other">CsA</term> blood concentrations was also observed when stimulation of <term id="A8" sem="Cell_natural">cells</term> was performed with <term id="T48" lex="interferon-gamma" sem="Protein_molecule">interferon-gamma</term> or <term id="T49" lex="interleukin-1beta" sem="Protein_molecule">interleukin-1beta</term>.</sentence>
<event id="E18">
<type class="Negative_regulation"/>
<theme idref="E35"/>
<cause idref="T47"/>
<clue><clueType>Inhibition</clueType> <linkTheme>of</linkTheme> TF induction <linkCause>in the presence of</linkCause> high CsA <clueLoc>blood</clueLoc> concentrations was also <clueKT>observed</clueKT> when stimulation of cells was performed with interferon-gamma or interleukin-1beta.</clue>
</event>
<event KT="Other" id="E35">
<type class="Positive_regulation"/>
<theme idref="T46"/>
<clue>Inhibition of TF <clueType>induction</clueType> in the presence of high CsA blood concentrations was also observed when stimulation of cells was performed with interferon-gamma or interleukin-1beta.</clue>
</event>
<event id="E19">
<type class="Physiological_process"/>
<theme idref="A8"/>
<cause idref="T48"/>
<clue>Inhibition of TF induction in the presence of high CsA blood concentrations was also observed when <clueType>stimulation</clueType> <linkTheme>of</linkTheme> cells was performed <linkCause>with</linkCause> interferon-gamma or interleukin-1beta.</clue>
</event>
<event id="E20">
<type class="Physiological_process"/>
<theme idref="A8"/>
<cause idref="T49"/>
<clue>Inhibition of TF induction in the presence of high CsA blood concentrations was also observed when <clueType>stimulation</clueType> <linkTheme>of</linkTheme> cells was performed <linkCause>with</linkCause> interferon-gamma or interleukin-1beta.</clue>
</event>
<event id="E21">
<type class="Negative_regulation"/>
<theme idref="E35"/>
<cause idref="E19"/>
<clue>Inhibition of TF induction in the presence of high CsA blood concentrations was also observed <linkCause>when</linkCause> stimulation of cells was performed with interferon-gamma or interleukin-1beta.</clue>
<comment>NO CLUETYPE</comment></event>
<event id="E22">
<type class="Negative_regulation"/>
<theme idref="E35"/>
<cause idref="E20"/>
<clue>Inhibition of TF induction in the presence of high CsA blood concentrations was also observed <linkCause>when</linkCause> stimulation of cells was performed with interferon-gamma or interleukin-1beta.</clue>
<comment>NO CLUETYPE</comment></event>
<sentence id="S8">As shown by <term id="T50" lex="reverse_transcription-polymerase_chain_reaction" sem="Other">reverse transcription-polymerase chain reaction</term> and <term id="T51" lex="electrophoretic_mobility_shift_assay" sem="Other">electrophoretic mobility shift assay</term>, respectively, treatment with <term id="T52" lex="CsA" sem="Organic_compound_other">CsA</term> leads to decreased <term id="T53" lex="TF_mRNA_expression" sem="Other"><term id="T54" lex="TF_mRNA" sem="RNA_molecule"><term id="T55" lex="TF" sem="Protein_family_or_group">TF</term> mRNA</term> expression</term> and reduced activation of the <term id="T56" lex="NF-kappaB_transcription_factor" sem="Protein_complex"><term id="T57" lex="NF-kappaB" sem="Protein_complex">NF-kappaB</term> transcription factor</term>, which is known to contribute to the induction of the <term id="T58" lex="TF_promotor" sem="DNA_domain_or_region"><term id="T59" lex="TF" sem="Protein_family_or_group">TF</term> promotor</term> in <term id="T60" lex="human_monocyte" sem="Cell_natural">human <term id="T61" lex="monocyte" sem="Cell_natural">monocytes</term></term>.</sentence>
<event id="E23">
<type class="Transcription"/>
<theme idref="T54"/>
<clue>As shown by reverse transcription-polymerase chain reaction and electrophoretic mobility shift assay, respectively, treatment with CsA leads to decreased TF mRNA <clueType>expression</clueType> and reduced activation of the NF-kappaB transcription factor, which is known to contribute to the induction of the TF promotor in human monocytes.</clue>
</event>
<event id="E24">
<type class="Positive_regulation"/>
<theme idref="T56"/>
<clue>As shown by reverse transcription-polymerase chain reaction and electrophoretic mobility shift assay, respectively, treatment with CsA leads to decreased TF mRNA expression and reduced <clueType>activation</clueType> <linkTheme>of</linkTheme> the NF-kappaB transcription factor, which is known to contribute to the induction of the TF promotor in human monocytes.</clue>
</event>
<event KT="Method" id="E41">
<type class="Artificial_process"/>
<theme idref="T52"/>
<clue>As shown by reverse transcription-polymerase chain reaction and electrophoretic mobility shift assay, respectively, <clueType>treatment</clueType> <linkTheme>with</linkTheme> CsA leads to decreased TF mRNA expression and reduced activation of the NF-kappaB transcription factor, which is known to contribute to the induction of the TF promotor in human monocytes.</clue>
</event>
<event id="E25">
<type class="Negative_regulation"/>
<theme idref="E23"/>
<cause idref="E41"/>
<clue>As shown <clueExperiment>by reverse transcription-polymerase chain reaction</clueExperiment> and electrophoretic mobility shift assay, respectively, treatment with CsA leads to <clueType>decreased</clueType> TF mRNA expression and reduced activation of the NF-kappaB transcription factor, which is known to contribute to the induction of the TF promotor in human monocytes.</clue>
</event>
<event id="E26">
<type class="Negative_regulation"/>
<theme idref="E24"/>
<cause idref="E41"/>
<clue>As shown <clueExperiment>by</clueExperiment> reverse transcription-polymerase chain reaction and <clueExperiment>electrophoretic mobility shift assay</clueExperiment>, respectively, treatment with CsA leads to decreased TF mRNA expression and <clueType>reduced</clueType> activation of the NF-kappaB transcription factor, which is known to contribute to the induction of the TF promotor in human monocytes.</clue>
</event>
<event KT="Other" id="E27">
<type class="Positive_regulation"/>
<theme idref="T58"/>
<clue>As shown by reverse transcription-polymerase chain reaction and electrophoretic mobility shift assay, respectively, treatment with CsA leads to decreased TF mRNA expression and reduced activation of the NF-kappaB transcription factor, which is known to contribute to the <clueType>induction</clueType> <linkTheme>of</linkTheme> the TF promotor <clueLoc>in human monocytes</clueLoc>.</clue>
</event>
<event KT="Fact" id="E39">
<type class="Positive_regulation"/>
<theme idref="E27"/>
<cause idref="T56"/>
<clue>As shown by reverse transcription-polymerase chain reaction and electrophoretic mobility shift assay, respectively, treatment with CsA leads to decreased TF mRNA expression and reduced activation of the NF-kappaB transcription factor, which is <clueKT>known</clueKT> to <clueType>contribute</clueType> <linkTheme>to</linkTheme> the induction of the TF promotor in human monocytes.</clue>
</event>
<sentence id="S9">CONCLUSIONS: This study demonstrates that <term id="T62" lex="TF_activation" sem="Other"><term id="T77" lex="TF" sem="Protein_family_or_group">TF</term> activation</term>, occurring in <term id="T64" lex="mononuclear_cell" sem="Cell_natural">mononuclear cells</term> of <term id="T65" lex="cardiac_transplant_recipient" sem="Multicellular_organism_natural">cardiac <term id="T66" lex="transplant_recipient" sem="Multicellular_organism_natural">transplant recipients</term></term>, is inhibited by treatment with <term id="T67" lex="CsA" sem="Organic_compound_other">CsA</term>.</sentence>
<event KT="Analysis" id="E28">
<type class="Negative_regulation"/>
<theme idref="E36"/>
<cause idref="T67"/>
<clue>CONCLUSIONS: This study <clueKT>demonstrates</clueKT> that TF activation, occurring <clueLoc>in mononuclear cells of cardiac transplant recipients</clueLoc>, is <clueType>inhibited</clueType> <linkCause>by</linkCause> treatment with CsA.</clue>
</event>
<event KT="Other" id="E36">
<type class="Positive_regulation"/>
<theme idref="T77"/>
<clue>CONCLUSIONS: This study demonstrates that TF <clueType>activation</clueType>, occurring in mononuclear cells of cardiac transplant recipients, is inhibited by treatment with CsA.</clue>
<comment>NER: T41 id mod, duplicated -&gt; T77</comment></event>
<sentence id="S10">Inhibition of <term id="T68" lex="monocyte_TF_induction" sem="Other"><term id="A9" sem="Cell_natural">monocyte</term> <term id="T69" lex="TF" sem="Protein_family_or_group">TF</term> induction</term> by <term id="T70" lex="CsA" sem="Organic_compound_other">CsA</term> may contribute to its successful use in <term id="T71" lex="cardiac_transplant_medicine" sem="Organic_compound_other">cardiac transplant medicine</term> and might be useful in managing further settings of <term id="T72" lex="vascular_pathology" sem="Other">vascular pathology</term> also known to involve <term id="T73" lex="TF_expression" sem="Other"><term id="T74" lex="TF" sem="Protein_family_or_group">TF</term> expression</term> and <term id="T75" lex="NF-kappaB_activation" sem="Other"><term id="T76" lex="NF-kappaB" sem="Protein_complex">NF-kappaB</term> activation</term>.</sentence>
<event KT="Other" id="E29">
<type class="Negative_regulation"/>
<theme idref="E37"/>
<cause idref="T70"/>
<clue><clueType>Inhibition</clueType> <linkTheme>of</linkTheme> monocyte TF induction <linkCause>by</linkCause> CsA may contribute to its successful use in cardiac transplant medicine and might be useful in managing further settings of vascular pathology also known to involve TF expression and NF-kappaB activation.</clue>
</event>
<event KT="Other" id="E37">
<type class="Positive_regulation"/>
<theme idref="T69"/>
<cause idref="A9"/>
<clue>Inhibition of <clueLoc>monocyte</clueLoc> TF <clueType>induction</clueType> by CsA may contribute to its successful use in cardiac transplant medicine and might be useful in managing further settings of vascular pathology also known to involve TF expression and NF-kappaB activation.</clue>
</event>
<event KT="Fact" id="E30">
<type class="Correlation"/>
<theme idref="T72"/>
<theme idref="E38"/>
<clue>Inhibition of monocyte TF induction by CsA may contribute to its successful use in cardiac transplant medicine and might be useful in managing further settings of vascular pathology also <clueKT>known</clueKT> to <clueType>involve</clueType> TF expression and NF-kappaB activation.</clue>
</event>
<event KT="Other" id="E38">
<type class="Gene_expression"/>
<theme idref="T74"/>
<clue>Inhibition of monocyte TF induction by CsA may contribute to its successful use in cardiac transplant medicine and might be useful in managing further settings of vascular pathology also known to involve TF <clueType>expression</clueType> and NF-kappaB activation.</clue>
</event>
<event KT="Fact" id="E31">
<type class="Correlation"/>
<theme idref="T72"/>
<theme idref="E32"/>
<clue>Inhibition of monocyte TF induction by CsA may contribute to its successful use in cardiac transplant medicine and might be useful in managing further settings of vascular pathology also <clueKT>known</clueKT> to <clueType>involve</clueType> TF expression and NF-kappaB activation.</clue>
</event>
<event KT="Other" id="E32">
<type class="Positive_regulation"/>
<theme idref="T76"/>
<clue>Inhibition of monocyte TF induction by CsA may contribute to its successful use in cardiac transplant medicine and might be useful in managing further settings of vascular pathology also known to involve TF expression and NF-kappaB <clueType>activation</clueType>.</clue>
</event>
</AbstractText>
</Abstract></Article></MedlineCitation></PubmedArticle></PubmedArticleSet></Annotation>
